Navigation Links
Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose
Date:8/28/2008

Warfarin could cut stroke risk by 67%, but patients and doctors say drug is hard to manage

THURSDAY, Aug. 28 (HealthDay News) -- Only 40 percent of patients with atrial fibrillation, a known risk factor for stroke, who did suffer a stroke were taking the anti-clotting drug warfarin, a new study found.

Among those taking warfarin, 75 percent weren't getting the dose needed to prevent a stroke. And an additional 25 percent were taking medications that were less effective at preventing clots or no medication at all, according to the report by Canadian researchers.

"These are missed opportunities for stroke prevention," lead researcher Dr. David J. Gladstone, a stroke neurologist at the University of Toronto, said in a prepared statement. "Sadly, we frequently see patients admitted to a hospital with a devastating stroke who are known to have atrial fibrillation, yet were either not taking warfarin or were taking a dose that is not therapeutic. We consider these to be potentially preventable strokes."

The findings are published online Aug. 29 in the journal Stroke.

Gladstone's team collected data on 2,135 stroke patients listed in the Registry of the Canadian Stroke Network. Among these patients, 597 were diagnosed with atrial fibrillation, an irregular heartbeat, before their stroke. For these patients, 60 percent of the strokes were disabling, and 20 percent were fatal.

Warfarin, by thinning the blood, helps prevent clots from developing and reduces the risk of stroke by about 67 percent in people with atrial fibrillation (AF). Strokes caused by AF can be more severe than other strokes, and studies have shown that warfarin can reduce the severity of strokes in patients with atrial fibrillation, the researchers said.

It's not clear why the rates of warfarin use were so low, the researchers said. "On one hand, we have an extremely effective and cheap medication for stroke prevention -- warfarin -- yet, on the other hand, it remains under-used in people who would benefit most from it," Gladstone said.

The study authors believe that efforts are needed to educate physicians and patients about the benefits of warfarin therapy for those with atrial fibrillation. "This is a public health priority, because atrial fibrillation is one of the most common causes of stroke," Gladstone said. "Many more strokes could be prevented if anti-coagulation therapy were optimized in the population at large."

Dr. Byron Lee, an assistant professor of cardiology at the University of California, San Francisco, thinks part of the problem may owe to the fact that many patients have problems taking warfarin, because it requires blood tests to monitor its effectiveness. Too low a dose is ineffective, while too high a dose can cause internal bleeding. So, patients need to have their warfarin levels measured at least once a month, he said.

"Patients hate taking warfarin, and doctors hate prescribing it," Lee said. "This is mainly because it's a hassle. However, this study confirms that many strokes can be avoided if patients are adequately anti-coagulated. Therefore, both patients and doctors need to do a better job of overcoming the inconvenience of warfarin."

Dr. John Worthington is a stroke physician at Liverpool and Northern Beaches Hospitals at the University of New South Wales in Sydney, Australia, who wrote an accompanying editorial in the journal. He said it's essential for patients with atrial fibrillation to receive warfarin to prevent a stroke.

"Warfarin is usually the best and safest available treatment to prevent stroke in people with atrial fibrillation. Increasing the uptake of warfarin would reduce the risk of death and disability of stroke," he said.

Worthington said patients with AF should ask their doctor why they aren't being prescribed warfarin.

More information

To learn more about atrial fibrillation visit the American Heart Association.



SOURCES: John Worthington, MB, Stroke Physician, Liverpool and Northern Beaches Hospitals, University of New South Wales, Sydney, Australia; Byron Lee, M.D., assistant professor of medicine, University of California, San Francisco; Aug. 28, 2008, online edition, Stroke


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Thousands of California Healthcare Workers Strike to Protect Their Patients
2. Heart attack patients who stop statin risk death, say McGill researchers
3. After Fits and Starts, New Hope for Psoriasis Patients
4. Brain surgery is getting easier on patients
5. Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome
6. Older Patients Less Likely to Be Taken to Trauma Centers
7. Olympic Gold Medalist Inspires Cancer Patients Through Blog
8. Hissey Kientz Concerned That Patients Have Not Been Provided With Crucial Information About Digitek Recall Despite the Dangers of Digoxin Toxicity
9. XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntingtons Disease
10. Hope for patients with COPD
11. Prototype test for predicting clinical outcome for melanoma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... Bill ... management industry in the coastal communities. After Tina Howe joined the team, the Bill ... happy employees, honest services at affordable rates, and giving back to the San Diego ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology: